2022 Fiscal Year Final Research Report
Dynamics of CXCL2 in anti-PD-1 antibody therapy
| Project/Area Number |
20K16317
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 肺癌 / PD-1 / PD-L1 / CXCL2 / CXCR2 / 免疫チェックポイント阻害薬 |
|---|
| Outline of Final Research Achievements |
CXCL2 secretion and expression of CXCR2 differed among different lung cancer cell lines. To confirm CXCL2 kinetics and immune cell profiles in the tumor microenvironment, anti-PD-1 antibody was administered to a tumor transplant mouse model. Anti-PD-1 antibody was administered to MC38 colon cancer model using C57BL/6 mice, and good tumor control effect was observed. CXCL2 changes before and after anti-PD-1 antibody administration correlated with tumor volume after administration. Flow cytometry confirmed MDSC expression in spleen and tumor tissue at the end of treatment. MDSC expression in the spleen was significantly lower in the PD-1 antibody-treated group than in the non-treated group.
|
| Free Research Field |
肺癌
|
| Academic Significance and Societal Importance of the Research Achievements |
現在肺癌に対して免疫チェックポイント阻害薬が幅広く使用されているが、その治療効果を予測するバイオマーカーの確立は十分とは言えない。我々は過去の研究において、CXCL2の変化が免疫チェックポイント阻害薬の効果と関係する事を報告している。今回の研究成果によりCXCL2動態と、それが腫瘍微小環境に対して与える影響が明らかになった。CXCL2は免疫チェックポイント阻害薬のバイオマーカーの候補となる可能性がある。
|
